SGS Announces Formulation and Stability Testing Services, New Labs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SGS Announces Formulation and Stability Testing Services, New Labs

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 2

SGS Life Science Services has announced new services for the integrated formulation and stability testing service for biologics that offer clients a program approach rather than project-based support. The services encompass pre/formulation preparation and testing, release/stability testing, troubleshooting expertise, higher order characterization and license application supporting studies, as well as stability indicating methods (forced degradation), administration support studies (such as extractables and leachables) and shipment support studies, according to a company press release.

The studies will be hosted by the SGS Life Science Services laboratories in Wokingham, UK; more than 7,000 sq ft of laboratories were built to accommodate the new services.

One new offering includes an upfront shipping route risk assessment, followed by conditioning and comprehensive product quality testing. The conditioning can be performed using an onsite automated thermal cycling chamber which can control temperature and humidity to a defined set point, such as ‑5°C, 0°C or +55°C/75 % RH, for anticipated exposure times. The chamber is also capable of supporting customer-specific requests and automated temperature cycling studies with a qualified operating range of ‑70°C to +180 °C and 10 % RH to 98 % RH.

SGS recently announced plans to open its fifth North American Life Science Services laboratory in Carson, Calif. This investment will establish a Life Science Services GMP/GLP laboratory, with the ability to provide microbiological testing and bioanalytical services. The new facility will encompass 8,000 sq ft, of which 6,000 sq ft will be dedicated laboratory space and remaining space for offices, conference rooms, and client records. The new facility is projected to open early in the third quarter of 2014 and will initially employ seven scientific staff, with room to expand as the demand grows.

Source: SGS Life Science Services

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here